Mr. Hardik Ghelani | Pharmacology | Best Researcher Award
Postdoc Fellow at Mohammed Bin Rashid University of Medicine and Health Sciences | United Arab Emirates
Dr. Hardik Ghelani is a pharmacology researcher and academic with an extensive multidisciplinary background spanning pharmacy, clinical research, pharmacology, and biomedical science. He holds a Bachelor of Pharmacy with distinction, a Master of Pharmacy specializing in Pharmacology, a Master of Science (Honours) from Western Sydney University, and a postgraduate diploma in clinical research, culminating in a doctoral degree in Pharmacology. His PhD work explored the therapeutic potential of curcumin in mitigating dyslipidemia associated with chronic kidney disease, demonstrating its ability to modulate key metabolic pathways, improve lipid profiles, and reduce renal injury in experimental models. After his doctoral training, he advanced his expertise further through a postdoctoral fellowship at the Ludwig Boltzmann Institute for Lung Vascular Research in Austria, where he investigated pulmonary vascular remodeling with a focus on aryl hydrocarbon receptor signaling and its relevance to pulmonary hypertension. Currently, he serves as a Postdoctoral Research Fellow at the College of Medicine at Mohammed Bin Rashid University of Medicine and Health Sciences in Dubai, contributing to both clinical and laboratory research. His ongoing projects include coordinating a randomized, placebo-controlled clinical trial assessing the anti-inflammatory effects of the sea-cucumber-derived nutraceutical Frondanol, evaluating the anticancer activity of marine and herbal bioactive compounds, and exploring microbiome–drug interactions involving metformin and licorice root extract in metabolic disorders. Dr. Ghelani is also actively engaged in academic teaching, manuscript development, grant writing, and collaborative translational research. His long-term scientific vision focuses on developing therapeutic strategies for chronic diseases using innovative chemical and natural product-based interventions.
Featured Publications:
Ghelani, H., Khursheed, M., Jan, R. K., & Adrian, T. E. (2023). Anti-inflammatory effects of bioactive compounds from seaweeds, bryozoans, jellyfish, shellfish and peanut worms. Marine Drugs.
Kaddoura, R., Ghelani, H., Alqutami, F., Altaher, H., Hachim, M., & Jan, R. K. (2023). Identification of specific biomarkers and pathways in the treatment response of infliximab for inflammatory bowel disease: In-silico analysis. Life.
Ghelani, H., Abdulhussain, Y., Henderson, H., Sudhir, M., Mascarenhas, S., Radhakrishnan, R., & Jan, R. K. (2022). The use and effectiveness of high-fidelity simulation in health professions education: Current update. Simulation.
Ghelani, H., Khursheed, M., Adrian, T. E., & Jan, R. K. (2022). Anti-inflammatory effects of compounds from echinoderms. Marine Drugs.
Ghelani, H., Alluri, R., Devi, S., Inampudi, V. K., Nammi, S., & others. (2020). Preclinical investigation of the acute effects of Trigonella foenum-graecum seed powder on blood glucose in normal and alloxan-induced diabetic rabbits. OBM Integrative and Complementary Medicine.